Poland
· Delayed Price · Currency is PLN Pure Biologics Statistics
Total Valuation
Pure Biologics has a market cap or net worth of PLN 59.22 million. The enterprise value is 71.69 million.
| Market Cap | 59.22M |
| Enterprise Value | 71.69M |
Important Dates
The next estimated earnings date is Wednesday, April 16, 2025.
| Earnings Date | Apr 16, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Pure Biologics has 3.75 million shares outstanding. The number of shares has increased by 14.31% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 3.75M |
| Shares Change (YoY) | +14.31% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 19.74% |
| Owned by Institutions (%) | 8.60% |
| Float | 2.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.60 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.67
| Current Ratio | 0.67 |
| Quick Ratio | 0.53 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.85 |
Financial Efficiency
Return on equity (ROE) is -1,111.15% and return on invested capital (ROIC) is -77.54%.
| Return on Equity (ROE) | -1,111.15% |
| Return on Assets (ROA) | -64.47% |
| Return on Invested Capital (ROIC) | -77.54% |
| Return on Capital Employed (ROCE) | 791.97% |
| Revenue Per Employee | -2.63M |
| Profits Per Employee | -4.98M |
| Employee Count | 51 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +27.84% in the last 52 weeks. The beta is 1.47, so Pure Biologics's price volatility has been higher than the market average.
| Beta (5Y) | 1.47 |
| 52-Week Price Change | +27.84% |
| 50-Day Moving Average | 16.59 |
| 200-Day Moving Average | 15.74 |
| Relative Strength Index (RSI) | 46.10 |
| Average Volume (20 Days) | 59,337 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pure Biologics had revenue of PLN -10.52 million and -19.92 million in losses. Loss per share was -5.93.
| Revenue | -10.52M |
| Gross Profit | -13.19M |
| Operating Income | -39.18M |
| Pretax Income | -44.70M |
| Net Income | -19.92M |
| EBITDA | -33.36M |
| EBIT | -39.18M |
| Loss Per Share | -5.93 |
Balance Sheet
The company has 1.28 million in cash and 13.75 million in debt, giving a net cash position of -12.47 million or -3.33 per share.
| Cash & Cash Equivalents | 1.28M |
| Total Debt | 13.75M |
| Net Cash | -12.47M |
| Net Cash Per Share | -3.33 |
| Equity (Book Value) | -4.98M |
| Book Value Per Share | -1.35 |
| Working Capital | -5.24M |
Cash Flow
| Operating Cash Flow | -10.38M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | 372.46% |
| Pretax Margin | 424.91% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Pure Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.31% |
| Shareholder Yield | -14.31% |
| Earnings Yield | -33.63% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pure Biologics has an Altman Z-Score of -25.12. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -25.12 |
| Piotroski F-Score | n/a |